Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    September 2019
  1. VOSHTANI R, Song M, Wang H, Li X, et al
    Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment.
    Cancer Lett. 2019;465:24-35.
    PubMed     Text format     Abstract available


    May 2019
  2. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed     Text format     Abstract available


    March 2019
  3. CHEN Y, Sumardika IW, Tomonobu N, Winarsa Ruma IM, et al
    Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
    Cancer Lett. 2019 Mar 20. pii: S0304-3835(19)30179.
    PubMed     Text format     Abstract available


    February 2019
  4. FENG Y, Sessions EH, Zhang F, Ban F, et al
    Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30084.
    PubMed     Text format     Abstract available


    January 2019
  5. BIANCHINI F, Portioli E, Ferlenghi F, Vacondio F, et al
    Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.
    Cancer Lett. 2019 Jan 10. pii: S0304-3835(19)30012.
    PubMed     Text format     Abstract available


    November 2018
  6. BRUMMER C, Faerber S, Bruss C, Blank C, et al
    Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Cancer Lett. 2018 Nov 24. pii: S0304-3835(18)30684.
    PubMed     Text format     Abstract available


  7. FURST K, Steder M, Logotheti S, Angerilli A, et al
    DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression.
    Cancer Lett. 2018;442:299-309.
    PubMed     Text format     Abstract available


    October 2018
  8. CHIU CS, Tsai CH, Hsieh MS, Tsai SC, et al
    Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and beta-catenin pathways.
    Cancer Lett. 2018 Oct 31. pii: S0304-3835(18)30640.
    PubMed     Text format     Abstract available


    September 2018
  9. SEIP K, Jorgensen K, Haselager MV, Albrecht M, et al
    "Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment".
    Cancer Lett. 2018 Sep 18. pii: S0304-3835(18)30580.
    PubMed     Text format     Abstract available


    July 2018
  10. QIU H, Zmina PM, Huang AY, Askew D, et al
    Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
    Cancer Lett. 2018 Jul 20. pii: S0304-3835(18)30482.
    PubMed     Text format     Abstract available


  11. LEE YS, Jung YY, Park MH, Yeo IJ, et al
    Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
    Cancer Lett. 2018;433:156-164.
    PubMed     Text format     Abstract available


    May 2018
  12. MEHTA PP, Kung PP, Yamazaki S, Walls M, et al
    Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".
    Cancer Lett. 2018;422:132.
    PubMed     Text format    


  13. ZHENG Y, Wang K, Wu Y, Chen Y, et al
    Pinocembrin induces ER stress mediated apoptosis and suppresses autophagy in melanoma cells.
    Cancer Lett. 2018;431:31-42.
    PubMed     Text format     Abstract available


    March 2018
  14. MARSAVELA G, Aya-Bonilla CA, Warkiani ME, Gray ES, et al
    Melanoma circulating tumor cells: Benefits and challenges required for clinical application.
    Cancer Lett. 2018;424:1-8.
    PubMed     Text format     Abstract available


  15. TANG J, Zhou H, Hou X, Wang L, et al
    Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
    Cancer Lett. 2018;423:16-26.
    PubMed     Text format     Abstract available


    January 2018
  16. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30051.
    PubMed     Text format     Abstract available


  17. DI GENNARO P, Gerlini G, Caporale R, Sestini S, et al
    T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
    Cancer Lett. 2018 Jan 3. pii: S0304-3835(18)30005.
    PubMed     Text format     Abstract available


    November 2017
  18. RODRIGUEZ CI, Castro-Perez E, Longley BJ, Setaluri V, et al
    Elevated cyclic AMP levels promote BRAF(CA)/Pten(-/-) mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30749.
    PubMed     Text format     Abstract available


    September 2017
  19. AIDA S, Sonobe Y, Tanimura H, Oikawa N, et al
    MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30555.
    PubMed     Text format     Abstract available


  20. HUANG GX, Wang Y, Su J, Zhou P, et al
    Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30552.
    PubMed     Text format     Abstract available


  21. KIM SJ, Jung KH, Son MK, Park JH, et al
    Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Cancer Lett. 2017;403:339-353.
    PubMed     Text format     Abstract available


    August 2017
  22. RUZZOLINI J, Peppicelli S, Andreucci E, Bianchini F, et al
    Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30487.
    PubMed     Text format     Abstract available


  23. WANG J, Hirose H, Du G, Chong K, et al
    P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.
    Cancer Lett. 2017 Aug 10. pii: S0304-3835(17)30478.
    PubMed     Text format     Abstract available


    July 2017
  24. CALERO R, Morchon E, Martinez-Argudo I, Serrano R, et al
    Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Cancer Lett. 2017 Jul 31. pii: S0304-3835(17)30457.
    PubMed     Text format     Abstract available


  25. PERES J, Maliepaard EM, Rambow F, Larue L, et al
    The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.
    Cancer Lett. 2017 Jul 28. pii: S0304-3835(17)30454.
    PubMed     Text format     Abstract available


  26. CIMAS FJ, Callejas-Valera JL, Garcia-Olmo DC, Hernandez-Losa J, et al
    E1a is an exogenous in vivo tumour suppressor.
    Cancer Lett. 2017;399:74-81.
    PubMed     Text format     Abstract available


  27. BORST A, Haferkamp S, Grimm J, Rosch M, et al
    Involvement of the BH3-only pro-apoptotic BIK/NBK in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Cancer Lett. 2017 Jul 15. pii: S0304-3835(17)30431.
    PubMed     Text format     Abstract available


  28. KUZU OF, Gowda R, Sharma A, Noory MA, et al
    Improving Pharmacological Targeting of AKT in Melanoma.
    Cancer Lett. 2017 Jul 10. pii: S0304-3835(17)30419.
    PubMed     Text format     Abstract available


  29. CALAPRE L, Warburton L, Milward M, Ziman M, et al
    Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Cancer Lett. 2017 Jul 4. pii: S0304-3835(17)30412.
    PubMed     Text format     Abstract available


    June 2017
  30. KLIMKIEWICZ K, Weglarczyk K, Collet G, Paprocka M, et al
    A 3D model of tumour angiogenic microenvironment to monitor hypoxia effects on cell interactions and cancer stem cell selection.
    Cancer Lett. 2017;396:10-20.
    PubMed     Text format     Abstract available


  31. LEE YK, Park UH, Kim EJ, Hwang JT, et al
    Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Cancer Lett. 2017 Jun 17. pii: S0304-3835(17)30396.
    PubMed     Text format     Abstract available


    April 2017
  32. WANG Y, Liu M, Jin Y, Jiang S, et al
    In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30289.
    PubMed     Text format     Abstract available


  33. LUO C, Shen J
    Research progress in advanced melanoma.
    Cancer Lett. 2017 Apr 3. pii: S0304-3835(17)30219.
    PubMed     Text format     Abstract available


  34. HOU X, Zhou H, Wang L, Tang J, et al
    Multifunctional near-infrared dye-magnetic nanoparticles for bioimaging and cancer therapy.
    Cancer Lett. 2017;390:168-175.
    PubMed     Text format     Abstract available


    February 2017
  35. XU DH, Zhu Z, Xiao H, Wakefield MR, et al
    Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Cancer Lett. 2017 Feb 28. pii: S0304-3835(17)30131.
    PubMed     Text format     Abstract available


  36. GUTTERIDGE RE, Singh CK, Ndiaye MA, Ahmad N, et al
    Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Cancer Lett. 2017 Feb 22. pii: S0304-3835(17)30121.
    PubMed     Text format     Abstract available


  37. DE SOUZA LM, Robertson BM, Robertson GP
    Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings.
    Cancer Lett. 2017 Feb 2. pii: S0304-3835(17)30064.
    PubMed     Text format     Abstract available


    January 2017
  38. PEARLMAN RL, Montes de Oca MK, Pal HC, Afaq F, et al
    Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
    Cancer Lett. 2017 Jan 25. pii: S0304-3835(17)30070.
    PubMed     Text format     Abstract available


    October 2016
  39. CHOLEWA BD, Ndiaye MA, Huang W, Liu X, et al
    Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer Lett. 2016 Oct 25. pii: S0304-3835(16)30646.
    PubMed     Text format     Abstract available


  40. GOWDA R, Sharma A, Robertson GP
    Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Cancer Lett. 2016 Oct 18. pii: S0304-3835(16)30628.
    PubMed     Text format     Abstract available


    September 2016
  41. LEE DG, Choi BK, Kim YH, Oh HS, et al
    The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential.
    Cancer Lett. 2016 Sep 5. pii: S0304-3835(16)30512.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: